Study on the effect of paclitaxel combined with carboplatin concurrent chemoradiotherapy in patients with esophageal cancer
Objective To study the clinical effect of concurrent chemoradiotherapy with paclitaxel combined with carbo-platin in patients with esophageal cancer.Methlds A total of 120 patients with esophageal cancer who received treat-ment in the Radiotherapy Department of the First Affiliated Hospital of Zhengzhou University from January 2020 to Janu-ary 2022 were randomly divided into the control group and the study group,with 60 cases in each group.The control group received concurrent chemoradiotherapy with carboplatin injection,and the study group received combined treat-ment with paclitaxel injection on the basis of the control group.The overall treatment effect,serum tumor markers,1-year survival,recurrence and adverse reactions were used as observation indexes to compare the treatment effect between groups.Results After treatment,the effective rate of the study group and the control group were 75.00％and 56.67％,respectively,and the effective rate of the study group was higher,the difference was statistically significant(P＜0.05).The levels of carcinoembryonic antigen(CEA)and carbohydrate antigen 19-9(CA19-9)were signifi-cantly decreased in the two groups before treatment(P＞0.05),and the levels of CEA and CA19-9 in the study group were(4.01±0.18)μg/L and(35.88±0.65)μ/mL,respectively,which were lower than those of the control group.The difference was statistically significant(P＜0.05).The 1-year survival rate of the study group was 95.00％higher than that of the control group,and the recurrence rate of 5.00％was lower than that of the control group,with statistical significance(P＜0.05).The incidence of adverse reactions in the study group and the control group was 21.67％and 16.67％,respectively,with no statistical signifi-cance(P＞0.05).Conclusion Simultaneous chemoradiotherapy with paclitaxel combined with carboplatin for esopha-geal cancer has significant efficacy,which can effectively reduce the level of serum tumor markers in patients,reduce the risk of recurrence,and improve the clinical survival rate of patients without significantly increasing adverse reac-tions.The overall efficacy is good and worthy of clinical promotion and application.
NETL
NSTL
万方数据
